Skip to main content
Contact Us
Subscribe
E-Edition
40°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lumos Pharma Inc
(NQ:
LUMO
)
4.300
-0.020 (-0.46%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lumos Pharma Inc
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
November 21, 2023
Webinar to be Held December 6, 2023 at 1:30pm EST
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
November 20, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
November 08, 2023
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all...
Via
Benzinga
What 7 Analyst Ratings Have To Say About Lumos Pharma
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Lumos Pharma
August 15, 2023
Via
Benzinga
Lumos Pharma: Q1 Earnings Insights
May 03, 2023
Via
Benzinga
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday.
Via
Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
November 08, 2023
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 08, 2023
Via
Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 08, 2023
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones.
Via
InvestorPlace
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
November 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 07, 2023
Via
Benzinga
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
November 07, 2023
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 30, 2023
Via
Benzinga
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
September 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
September 14, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Participation in Investor Conferences in September
September 07, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
August 22, 2023
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
August 09, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
July 26, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
July 12, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
June 29, 2023
Via
Benzinga
Lumos Pharma Announces Departure of Chief Medical Officer
June 28, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
June 21, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
May 31, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
May 25, 2023
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma to Participate in World Orphan Drug Congress USA
May 22, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
May 08, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
May 03, 2023
From
Lumos Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.